This week, Ira spoke with Gemma Stafford & Kevin Kurtz from “Bigger Bolder Baking.” In this blended episode of “Ira’s Everything Bagel,” Gemma and Kevin talk about Gem-ma’s early passion for cooking and baking and Kevin’s passion for the entertainment business; how they met and decided to create a baking website as well as a channel on YouTube; writing two cook-books; their connection with their global audience (who are home bakers); and their plans for a baking network.
This week, Ira spoke with Dhaval Desai, M.D., author of “Burning Out On The Covid Front Lines, a Doctor’s Memoir of Fatherhood, Race and Perseverance in the Pandemic.” In this recuperative episode of “Ira’s Everything Bagel,” Dr. Desai talks about why he decided to write this personal account of his experiences as a doctor during the pandemic; the uncertainty of dealing with the phenomenon, where guidelines changed often; how he dealt with his own mental health during the crisis; where race may be an issue from his perspective; and what lessons he would like readers to take from his personal and professional struggles.
This week, Ira spoke with Charles Scribner III, author of “Scribners: Five Generations in Publishing.” In this generational episode of “Ira’s Everything Bagel,” Charles talks about why he wrote the book; how he wrote it in one month; why it’s not a comprehensive history, but a family historical memoir; how his father was his greatest teacher; his father’s relationship with Ernest Hemingway; how books affect lives; why Max Perkins was the greatest editor of the 20th century; and the future of books.
This week, Ira spoke with Antonio Ciaccia, president of 3 Axis Advisors, which conducted a study to determine how prescription prices are being set. In this prescriptive episode of “Ira’s Everything Bagel,” Anthony talks about the results of the study, which concluded that the overwhelming majority of prices paid by consumers at the pharmacy counter are based on price points established by health insurance corporation intermediaries known as pharmacy benefit managers (PBMs); why, in a broader eco system, we’re supposed to overpay for brand drugs; how health insurance companies and PBMs, brought in to contain costs, actually do the opposite; and why he proposes more transparency and an end to the exemption to the “anti-kickback” law.